Back to search

Article

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma

2023-10-01

Abstract excerpt

Lung adenocarcinoma (LUAD), commonly driven by KRAS mutations, is responsible for 7% of all cancer mortality. The first allele-specific KRAS inhibitors were recently approved in LUAD, but clinical benefit is limited by intrinsic and acquired resistance. LUAD predominantly arises from alveolar type 2 (AT2) cells, which function as facultative alveolar stem cells by self-renewing and replacing alveolar type 1 (AT1)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f6d9c349-4360-53bd-af36-3f26d07df383
DOI
10.1101/2023.09.29.560194
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinomaDOI 10.1101/2023.09.29.560194
Select a neighboring publication to make it the new centre.